0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-L1

PD-L1

PD-L1 Molecule Information

Name:Programmed death-ligand 1
Target Synonym:Programmed death ligand 1?B7 homolog 1?CD_antigen=CD274?Programmed cell death 1 ligand 1?B7H1 ?PDCD1L1?PDCD1LG1?CD274?PD-L1?B7-H1?PDL1?PDCD1 ligand 1
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:50
Lastest Research Phase:Approved

PD-L1 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 Protein, His,Avitag™
PDL-H82E4-structure
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin
PDL-H5250-structure
PDL-H5250-sds
PDL-H5250-elisa_1
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™
PDL-H82F2-structure
PDL-H82F2-sds
PDL-H82F2-elisa_1
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, mouse IgG2a Fc Tag, low endotoxin
PD1-M52A2-structure
PD1-M52A2-sds
PD1-M52A2-elisa_1
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (recommended for biopanning)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-H82E5-elisa_1
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M82F5-elisa_1
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag
PD1-M5220-structure
PD1-M5220-sds
PD1-M5220-elisa_2
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag
PD1-M5251-structure
PD1-M5251-sds
PD1-M5251-elisa_1
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (HPLC-verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-H52A3-hplc
PD1-H52A3-elisa_1
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C52H4-elisa_1
PD1-C52H4-elisa_2
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag
PD1-C5253-structure
PD1-C5253-sds
PD1-C5253-elisa_1
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H82F3-elisa_1
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Strep Tag
PD1-H5282-structure
PD1-H5282-sds
PD1-H5282-elisa_1
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (HPLC-verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5258-hplc
PD1-H5258-elisa_1
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (HPLC verified)
PD1-H5229-structure
PD1-H5229-sds
PD1-H5229-hplc
PD1-H5229-elisa_1
PD1-H5229-elisa_2

PD-L1 Molecule Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

PD-L1 Molecule Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

PD-L1 References

PD-L1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Atezolizumab MPDL-3280A; RG-7446; RO-5541267; 52CMI0WC3Y (UNII code) ,MPDL3280A,RG7446 Approved Genentech TECENTRIQ fda Urothelial cancer GENENTECH INC 2016-05-18 Triple negative breast cancer, Non small cell lung cancer (NSCLC), Urothelial cancer Details
Durvalumab MEDI-4736,MEDI4736,28X28X9OKV (UNII code) Approved MedImmune, Celgene IMFINZI fda Urothelial cancer ASTRAZENECA UK LTD 2017-05-01 Non small cell lung cancer (NSCLC), Urothelial cancer Details
Avelumab MSB-0010718C; PF-06834635 ,MSB0010718C,PF06834635  Approved Merck Serono, Pfizer BAVENCIO fda Merkel cell carcinoma EMD SERONO INC 2017-03-23 Merkel cell carcinoma, Urothelial cancer Details

PD-L1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Pd-1-pik Pd-1-pik Phase Ⅰ Huashan Hospital of Fudan University Glioblastoma multiforme Details
Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) STI-A1014; ZKAB-001,STIA1014; ZKAB001; STIA-1014 Phase Ⅱ Zhaoke Oncology Urothelial cancer, Solid tumours, Osteosarcoma, Cervical carcinoma Details
CA-327 CA-327; AUPM-327 Preclinical Aurigene, Curis Cancer Details
JS-003 JS-003,JS003; JS 003 Phase Ⅰ Shanghai Junshi Biosciences Solid tumours Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Phase Ⅰ Bristol-Myers Squibb Sepsis Details
Bintrafusp alfa M-7824; MSB0011359C,M7824; MSB-0011359C Phase Ⅱ Merck Serono, GlaxoSmithKline Prostate cancer, Solid tumours Details
Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology) Phase Ⅰ Marino Biotechnology Solid tumours, Glioblastoma Details
CA-170 CA-170; AUPM-170 Phase Ⅱ Aurigene, Curis Cancer Details
89Zr-durvalumab Phase Ⅱ Radboud University Head and neck cancer Details
KN-046 KN-046,KN046; KN 046 Phase Ⅱ Alphamab Non small cell lung cancer (NSCLC), Solid tumours Details
LOR-S03 CDX-527; LOR-A04; LOR-S01; LOR-S03 Preclinical Celldex Cancer Details
PD-L1 t-haNK cell therapy Phase Ⅰ NantKwest Solid tumours Details
Recombinant humanized PD-L1 single domain antibody Fc fusion protein KN035;ASC-22;KN-035;ASC22 Phase Ⅲ Alphamab, 3D Medicines, Ascletis Septic shock, Sepsis, Biliary cancer Details
CX-072 CX-072,CX072 Phase Ⅱ CytomX Therapeutics Solid tumours, Lymphoma Details
SHR-1701 SHR-1701,SHR1701; SHR 1701 Phase Ⅰ Jiangsu Hengrui Medicine Castration-resistant prostate cancer (CRPC), Malignancies Details
BGB-A333 BGB-A333,BGBA333 Phase Ⅱ BeiGene Solid tumours Details
GR-1405 GR-1405,GR1405; GR 1405 Phase Ⅰ Chongqing Genrix Biopharmaceutical, Genrix (Shanghai) Biopharmaceutical Solid tumours, Lymphoma Details
Anti PD-L1 monoclonal antibody (Biocad) BCD-135 Phase Ⅰ Biocad Solid tumours Details
Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) HS-636 Phase Ⅰ Hisun Pharm Cancer Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase Ⅰ Hunan Zhaotai Yongren Biotech Non small cell lung cancer (NSCLC) Details
Human source and Fc engineered monoclonal antibody (MabSpace) MSB-2311,MSB2311 Phase Ⅰ MabSpace Biosciences Solid tumours Details
Durvalumab/Osimertinib Mesylate Phase Ⅲ MedImmune Non small cell lung cancer (NSCLC) Details
IGV-001 IGV-001 Phase Ⅰ Imvax Glioblastoma Details
FAZ-053 FAZ-053,FAZ053 Phase Ⅰ Novartis Solid tumours Details
FS 118 FS-118 Phase Ⅰ F-star, Merck Serono hematological malignancies, Solid tumours Details
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) Phase Ⅰ Sanjin Pharmaceutical, Adagene Cancer Details
ES101 ES101 Phase Ⅰ Inhibrx, Elpiscience Solid tumours Details
Anti-PDL1 monoclonal antibody (TG Therapeutics) TG-1501 Phase Ⅰ TG Therapeutics Cancer Details
BMS-936559 BMS-936559; MDX-1105; Anti-PD-L1,BMS936559; MDX1105 Phase Ⅱ Bristol-Myers Squibb Sepsis Details
SHR-1316 SHR-1316 Phase Ⅲ Jiangsu Hengrui Medicine Small cell lung cancer (SCLC), Esophagus cancer, Solid tumours Details
Recombinant humanized PD-L1 monoclonal antibody LP-002,LP002; LP 002 Phase Ⅰ Taizhou Houde Aoke Technology Solid tumours Details
IBI318 IBI318; IBI-318 Phase Ⅰ Innovent Biologics, Lilly Malignancies Details
LY-3300054 LY-3300054 Phase Ⅰ Lilly Solid tumours Details
CS-17938 CS17938 Preclinical ChipScreen Immunological disorders, Cancer Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase Ⅲ CBT, Chiatai Tianqing (CTTQ) Triple negative breast cancer, Non small cell lung cancer (NSCLC), Solid tumours, Liver cancer, Hodgkin lymphoma, Head and neck cancer, Biliary cancer Details
MCLA-145 MCLA-145 Phase Ⅰ Incyte, Merus Cancer Details
A167 KL-A167; A167,A-167,KL A167 Phase Ⅱ Sichuan Kelunbotai Biopharmaceutical, Harbour BioMed Nasopharyngeal cancer, Lymphoma, Hodgkin lymphoma Details
Y-111 Y-111 Preclinical YZY Bio Non small cell lung cancer (NSCLC), Melanoma Details
KD-045 (Nanjing KAEDI Biotech) KD-045 Phase Ⅰ Nanjing KAEDI Biotech Solid tumours Details
IMC-001 STI-3031; IMC-001,IMC001,IMC 001 Phase Ⅰ Sorrento Therapeutics, ImmuneOncia Therapeutics Solid tumours Details
Durvalumab/Selumetinib Phase Ⅰ AstraZeneca Solid tumours Details
Durvalumab/Gefitinib Phase Ⅱ MedImmune Non small cell lung cancer (NSCLC) Details
18F-BMS-986192 BMS-986192-[18F] Phase Not Specified Bristol-Myers Squibb Cancer Details
INBRX-105 INBRX-105 Phase Ⅰ Inhibrx Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Urothelial cancer, Esophageal adenocarcinoma, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma, Melanoma Details
Recombinant human anti-PDL1 monoclonal antibody (CStone Pharmaceuticals) CS-1001,WBP-3155 Phase Ⅲ CStone Pharmaceuticals Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Solid tumours, Lymphoma, Gastroesophageal junction adenocarcinoma, Hodgkin lymphoma Details
HLX-20 HLX-20,HLX20; HLX 20 Phase Ⅰ Shanghai Henlius Biotech Solid tumours Details
REMD-290 REMD-290 Preclinical REMD Biotherapeutics, Buchang Pharma Cancer Details
CK-301 CK-301,CK301 Phase Ⅰ Dana-Farber Cancer Institute, Checkpoint Non small cell lung cancer (NSCLC), Renal cell carcinoma, Merkel cell carcinoma, Urothelial cancer, Mesothelioma, Hodgkin lymphoma, Head and neck cancer, Melanoma Details
GEN-1046 DuoBody-PD-L1x4-1BB; GEN1046; PD-L1x4-1BB Phase Ⅱ Genmab, BioNTech Triple negative breast cancer, Non small cell lung cancer (NSCLC), Endometrial cancer, Urothelial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Cervical carcinoma Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase Ⅰ The Second Hospital of Nanjing Medical University Primary hepatocellular carcinoma Details

This web search service is supported by Google Inc.

totop